Introduction
Major Wall Street firms have delivered a series of bullish upgrades this week, with analysts from Guggenheim, Citi, JPMorgan, and Wells Fargo raising ratings on Uber, Logitech, DoorDash, and Apellis Pharmaceuticals. These upgrades come amid mixed market performance, highlighting specific growth catalysts and improving fundamentals across the technology, delivery, and pharmaceutical sectors that analysts believe position these companies for significant upside.
Key Points
- Guggenheim upgraded Uber to Buy with $140 target, citing 3x larger network than peers and autonomous vehicle positioning
- DoorDash's Deliveroo acquisition expands its footprint to 45 countries serving over 1 billion people and 50 million monthly users
- Citi sees Logitech benefiting from positive PC trends, videoconferencing equipment demand, and strong gaming peripheral sales
Uber's Dominant Network Position Drives Guggenheim Upgrade
Guggenheim analysts upgraded Uber to a buy rating with a $140 price target, representing substantial upside from Tuesday’s closing price of $94.25. The firm’s bullish thesis centers on Uber’s “asset base consisting of industry-leading 1) network, 2) technology, and 3) brand equity.” According to Guggenheim, Uber’s multi-platform network is more than three times larger than its next closest gig economy peer, positioning the rideshare leader advantageously for increased autonomous vehicle adoption.
The upgrade suggests analysts see Uber retesting its recent high of $100.18 per share as an initial target. This endorsement comes at a time when technology stocks are showing resilience, with the Nasdaq Composite surging 0.39% to 22,608.73 in Wednesday’s trading session, propelled by AI chip leaders including Nvidia, Intel, and AMD.
Logitech Benefits from Improving Peripheral Demand
Citi analysts upgraded Logitech from neutral to buy with a $130 price target, implying approximately 25% upside potential from its last trading price of $104.94. The firm cited an improving environment for peripherals, noting that “peripheral demand should benefit given positive PC data points with checks suggesting constructive Videoconferencing equipment demand amidst return to office, and strong gaming peripherals demand.”
This upgrade reflects broader technology sector momentum, underscored by a $40 billion BlackRock-led buyout of a major data-center firm. For Logitech specifically, the combination of return-to-office trends driving videoconferencing equipment demand and sustained gaming peripheral strength creates a compelling growth narrative. Analysts anticipate the stock will initially retest the $115 per share level.
DoorDash's Global Expansion Following Deliveroo Acquisition
JPMorgan upgraded DoorDash to an outperform rating, expressing bullish sentiment following the company’s acquisition of Deliveroo. The strategic move significantly expands DoorDash’s international footprint, with the combined entity now operating in 45 countries serving a combined population of over one billion people. The acquisition brings DoorDash’s total reach to more than 700,000 local businesses and 50 million monthly active users, with Deliveroo contributing approximately seven million of those users.
This massive scale expansion positions DoorDash for accelerated growth in international markets, potentially driving significant revenue diversification beyond its core U.S. operations. The upgrade comes during a period of mixed market performance, where the Dow slipped despite robust bank earnings from Bank of America and Morgan Stanley, while the S&P 500 edged up 0.21% to 6,658.43.
Apellis Pharmaceuticals Sees Wells Fargo Upgrade
Wells Fargo upgraded Apellis Pharmaceuticals to overweight with a $32 price target, citing “stabilizing Syfovre sales and its confidence in Empaveli’s launch following a doctor survey.” The firm believes Apellis shares could rally 15%-20% based on Empaveli’s growth potential, representing significant upside for investors in the pharmaceutical sector.
This upgrade highlights the ongoing analyst focus on companies with specific catalysts that can drive near-term performance. While technology and delivery stocks captured most of the upgrade attention this week, Apellis Pharmaceuticals demonstrates that Wall Street remains bullish on pharmaceutical companies with promising drug launches and stabilizing existing product sales.
📎 Related coverage from: 247wallst.com
